| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |